These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 12655261)

  • 1. Effects of selective COX-2 inhibitors on the gastric permeability of sucrose: a controlled study with placebo and ibuprofen.
    Ekenel M; Avşar E; Imeryüz N; Yüksel M; Haklar G; Kocakaya O; Tözün N
    Eur J Gastroenterol Hepatol; 2003 Apr; 15(4):403-6. PubMed ID: 12655261
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.
    Silverstein FE; Faich G; Goldstein JL; Simon LS; Pincus T; Whelton A; Makuch R; Eisen G; Agrawal NM; Stenson WF; Burr AM; Zhao WW; Kent JD; Lefkowith JB; Verburg KM; Geis GS
    JAMA; 2000 Sep; 284(10):1247-55. PubMed ID: 10979111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial.
    Simon LS; Weaver AL; Graham DY; Kivitz AJ; Lipsky PE; Hubbard RC; Isakson PC; Verburg KM; Yu SS; Zhao WW; Geis GS
    JAMA; 1999 Nov; 282(20):1921-8. PubMed ID: 10580457
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized, controlled comparison of ibuprofen at the maximal over-the-counter dose compared with prescription-dose celecoxib on upper gastrointestinal mucosal injury.
    Scheiman JM; Cryer B; Kimmey MB; Rothstein RI; Riff DS; Wolfe MM
    Clin Gastroenterol Hepatol; 2004 Apr; 2(4):290-5. PubMed ID: 15067622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biochemical and clinical evidence that aspirin-intolerant asthmatic subjects tolerate the cyclooxygenase 2-selective analgetic drug celecoxib.
    Gyllfors P; Bochenek G; Overholt J; Drupka D; Kumlin M; Sheller J; Nizankowska E; Isakson PC; Mejza F; Lefkowith JB; Dahlén SE; Szczeklik A; Murray JJ; Dahlén B
    J Allergy Clin Immunol; 2003 May; 111(5):1116-21. PubMed ID: 12743579
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the efficacy and tolerability of dexibuprofen and celecoxib in the treatment of osteoarthritis of the hip.
    Hawel R; Klein G; Singer F; Mayrhofer F; Kähler ST
    Int J Clin Pharmacol Ther; 2003 Apr; 41(4):153-64. PubMed ID: 12708604
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NSAID-induced gastric damage in rats: requirement for inhibition of both cyclooxygenase 1 and 2.
    Wallace JL; McKnight W; Reuter BK; Vergnolle N
    Gastroenterology; 2000 Sep; 119(3):706-14. PubMed ID: 10982765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of acute low back pain with the COX-2-selective anti-inflammatory drug nimesulide: results of a randomized, double-blind comparative trial versus ibuprofen.
    Pohjolainen T; Jekunen A; Autio L; Vuorela H
    Spine (Phila Pa 1976); 2000 Jun; 25(12):1579-85. PubMed ID: 10851109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic gastric ulcer healing in rats subjected to selective and non-selective cyclooxygenase-2 inhibitors.
    Berenguer B; Alarcón de la Lastra C; Moreno FJ; Martín MJ
    Eur J Pharmacol; 2002 May; 442(1-2):125-35. PubMed ID: 12020690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs?
    Jüni P; Rutjes AW; Dieppe PA
    BMJ; 2002 Jun; 324(7349):1287-8. PubMed ID: 12039807
    [No Abstract]   [Full Text] [Related]  

  • 11. Acute gastrointestinal permeability responses to different non-steroidal anti-inflammatory drugs.
    Smecuol E; Bai JC; Sugai E; Vazquez H; Niveloni S; Pedreira S; Mauriño E; Meddings J
    Gut; 2001 Nov; 49(5):650-5. PubMed ID: 11600467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of celecoxib on ambulatory blood pressure in hypertensive patients on ACE inhibitors.
    White WB; Kent J; Taylor A; Verburg KM; Lefkowith JB; Whelton A
    Hypertension; 2002 Apr; 39(4):929-34. PubMed ID: 11967252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis.
    Steinbach G; Lynch PM; Phillips RK; Wallace MH; Hawk E; Gordon GB; Wakabayashi N; Saunders B; Shen Y; Fujimura T; Su LK; Levin B; Godio L; Patterson S; Rodriguez-Bigas MA; Jester SL; King KL; Schumacher M; Abbruzzese J; DuBois RN; Hittelman WN; Zimmerman S; Sherman JW; Kelloff G
    N Engl J Med; 2000 Jun; 342(26):1946-52. PubMed ID: 10874062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial.
    Bensen WG; Fiechtner JJ; McMillen JI; Zhao WW; Yu SS; Woods EM; Hubbard RC; Isakson PC; Verburg KM; Geis GS
    Mayo Clin Proc; 1999 Nov; 74(11):1095-105. PubMed ID: 10560596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence of gastroduodenal ulcers associated with valdecoxib compared with that of ibuprofen and diclofenac in patients with osteoarthritis.
    Sikes DH; Agrawal NM; Zhao WW; Kent JD; Recker DP; Verburg KM
    Eur J Gastroenterol Hepatol; 2002 Oct; 14(10):1101-11. PubMed ID: 12362101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized trial measuring fecal blood loss after treatment with rofecoxib, ibuprofen, or placebo in healthy subjects.
    Hunt RH; Bowen B; Mortensen ER; Simon TJ; James C; Cagliola A; Quan H; Bolognese JA
    Am J Med; 2000 Aug; 109(3):201-6. PubMed ID: 10974182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. COX-2-Selective NSAIDs: new and improved?
    Lichtenstein DR; Wolfe MM
    JAMA; 2000 Sep; 284(10):1297-9. PubMed ID: 10980759
    [No Abstract]   [Full Text] [Related]  

  • 18. Update on clinical developments with celecoxib, a new specific COX-2 inhibitor: what can we expect?
    Geis GS
    Scand J Rheumatol Suppl; 1999; 109():31-7. PubMed ID: 10422544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. COX-2 inhibition with rofecoxib does not increase intestinal permeability in healthy subjects: a double blind crossover study comparing rofecoxib with placebo and indomethacin.
    Sigthorsson G; Crane R; Simon T; Hoover M; Quan H; Bolognese J; Bjarnason I
    Gut; 2000 Oct; 47(4):527-32. PubMed ID: 10986213
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: a double-blind trial.
    Laine L; Maller ES; Yu C; Quan H; Simon T
    Gastroenterology; 2004 Aug; 127(2):395-402. PubMed ID: 15300570
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.